



Cancer Chemotherapy and Biological Response Modifiers

Annual 22

**Editors: G. Giaccone, R. Schilsky,
P. Sondej**

Cancer Chemotherapy and Biological Response Modifiers Annual 22

Edited by

G. Giaccone

Academic Hospital Vrije Universiteit
Amsterdam, The Netherlands

R. Schilsky

University of Chicago
Chicago, IL, U.S.A

P. Sondel

University of Wisconsin
Madison, WI, U.S.A.

Honorary Editors: H.M. Pinedo, D.L. Longo, B.A. Chabner



2005

Elsevier

Amsterdam – Boston – Heidelberg – London – New York – Oxford – Paris
San Diego – San Francisco – Singapore – Sydney – Tokyo

ELSEVIER B.V.
Radarweg 29
P.O. Box 211, 1000 AE Amsterdam
The Netherlands

ELSEVIER Inc.
625 Walnut Street
Philadelphia, PA 19106
USA

ELSEVIER Ltd
The Boulevard, Langford Lane
Kidlington, Oxford OX5 1GB
UK

ELSEVIER Ltd
84 Theobalds Road
London WC1X 8RR
UK

© 2005 Elsevier B.V. All rights reserved.

This work is protected under copyright by Elsevier B.V., and the following terms and conditions apply to its use:

Photocopying

Single photocopies of single chapters may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier's Rights Department in Oxford, UK: phone (+44) 1865 843830, fax (+44) 1865 853333, e-mail: permissions@elsevier.com. Requests may also be completed on-line via the Elsevier homepage (<http://www.elsevier.com/locate/permissions>).

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (+1) (978) 7508400, fax: (+1) (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 20 7631 5555; fax: (+44) 20 7631 5500. Other countries may have a local reprographic rights agency for payments.

Derivative Works

Tables of contents may be reproduced for internal circulation, but permission of the publisher is required for external resale or distribution of such material. Permission of the Publisher is required for all other derivative works, including compilations and translations.

Electronic Storage or Usage

Permission of the Publisher is required to store or use electronically any material contained in this work, including any chapter or part of a chapter.

Except as outlined above, no part of this work may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

Address permissions requests to: Elsevier's Rights Department, at the fax and e-mail addresses noted above.

Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drugs dosages should be made.

First edition 2005

Library of Congress Cataloging in Publication Data

A catalog record is available from the Library of Congress.

British Library Cataloguing in Publication Data

A Catalogue record is available from the British Library.

ISBN: 0-444-51883-5

ISSN: 0921-4410

© The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).
Printed in The Netherlands.

**Cancer Chemotherapy
and Biological Response
Modifiers Annual 22**

Contributors

A.A. Adjei
Division of Medical Oncology
Mayo Clinic, 200 First Street SW
Rochester, MN 55905
USA
e-mail: adjei.alex@mayo.edu

M. Al-Sarraf
Clinical Professor of Medicine
Wayne State University, Wm. Beaumont
Hospital, 3577 W. 13 Mile Road #404
Royal Oak, MI 48073
USA
e-mail: mdalsarraf@aol.com

M.R. Albertini
University of Wisconsin Comprehensive
Cancer Center
600 Highland Avenue, K4/414
Madison, WI 53792
USA
e-mail: mralbert@facstaff.wisc.edu

R. Angioli
Department of Obstetrics & Gynaecology
University 'Campus Biomedico'
00155 Rome
Italy
e-mail: R.Angioli@unicampus.it

L.S. Ashby
Barrow Neurological Institute
500 West Thomas Street, Suite 300
Phoenix, AZ 85013
USA
e-mail: lashby@chw.edu

M.B. Atkins
Beth Israel Deaconess Medical Center
Harvard Medical School, Kirstein 158
330 Brookline Avenue
Boston, MA 02215
USA

J. Baselga
Medical Oncology Service
Vall d'Hebron University Hospital
Universitat Autònoma de Barcelona
P. Vall d'Hebron 119-129
08035 Barcelona
Spain
e-mail: jbaselga@vhebron.net

Savitha Balaraman
Senior Fellow of Oncology
Department of Medicine,
Wm. Beaumont Hospital
Wayne State University
3577 W. 13 Mile Road #404
Royal Oak, MI 48073
USA

G. Batist
The Montreal Center for Experimental
Therapeutics in Cancer
McGill University and The Lady Davis Institute
for Medical Research
D-127, Sir Mortimer B. Davis – Jewish
General Hospital
3755 Chemin Cote Ste Catherine
Montreal, Quebec
Canada, H3T-1E2

M. Bower
Department of Oncology
Chelsea & Westminster Hospital
369 Fulham Road
London, SW10 9NH
UK
e-mail: m.bower@ic.ac.uk

C. Brown
Cancer Immunotherapeutic Program
City of Hope NCI-Designated
Comprehensive Cancer Center
City of Hope Beckman Research Institute &
National Medical Center

Duarte, CA
USA

L. Castagna
Associate Director
Department of Medical Oncology
and Hematology
Istituto Clinico Humanitas
Via Manzoni 56
20089 Rozzano-Milano
Italy

P.B. Chapman
Department of Medicine & Swim Across
America Laboratory
Memorial Sloan-Kettering Cancer Center
New York, NY 10021
USA
e-mail: chapmanp@mskcc.org

J. Chi-feng Hsu
Department of Immunology
Roswell Park Cancer Institute
Elam & Carlton Streets
Buffalo, NY 14263
USA

A.D. Cohen
Clinical Immunology
Department of Medicine
Memorial Sloan-Kettering Cancer Center and
Weill Medical College of Cornell University
1275 York Avenue
New York, NY 10021
USA

L.J.N. Cooper
Cancer Immunotherapeutic Program
City of Hope NCI-Designated
Comprehensive Cancer Center
City of Hope Beckman Research Institute &
National Medical Center
Duarte, CA
USA

J. Cortes
Medical Oncology Service
Vall d'Hebron University Hospital
Universitat Autònoma de Barcelona

P. Vail d'Hebron 119-129
08035 Barcelona
Spain

E.D. Crawford
Department of Urologic Oncology
1665 North Ursula Street, Suite 1004
Aurora, CO 80010
USA

P.A. Davol
Immunotherapy Program
Adele R. Decof Cancer Center
North Campus Room G01, Roger Williams
Hospital, 825 Chalkstone Avenue
Providence, RI 02908
USA

S. Diggikar
Associate Professor
University of Texas Health Science Center
at San Antonio Cancer Therapy &
Research Center
7979 Wurzbach Road, Room Z415
San Antonio, TX 78229
USA

D. DiGiusto
Cancer Immunotherapeutic Program
City of Hope NCI-Designated Comprehensive
Cancer Center
City of Hope Beckman Research Institute &
National Medical Center
Duarte, CA
USA

A.M.M. Eggermont
Professor of Surgical Oncology
Department of Surgical Oncology
Erasmus University Medical Center –
Daniel den Hoed Cancer Center
301 Groene Hilledijk,
3075 EA Rotterdam
The Netherlands
e-mail: a.m.m.eggermont@erasmusmc.nl

O. Eton
Department of Melanoma
Division of Cancer Medicine

University of Texas, MD Anderson
Cancer Center, 1515 Holcombe Blvd,
Box 430, Houston, TX 77030
USA
e-mail: oeton@mdanderson.org

G. Favalli
Department of Obstetrics & Gynaecology
Division of Gynaecology & Oncology
University of Brescia
Italy

S. Ferrone
Department of Immunology
Roswell Park Cancer Institute
Elam & Carlton Streets
Buffalo, NY 14263
USA
e-mail: soldano.ferrone@roswellpark.org

M. Fink
160 East 32nd Street
New York, NY 10016
USA

S.J. Forman
Cancer Immunotherapeutic Program
City of Hope NCI-Designated Comprehensive
Cancer Center
City of Hope Beckman Research
Institute & National Medical Center
Duarte, CA
USA

G. Giaccone
Division of Medical Oncology
Vrije Universiteit Medical Center
1117 De Boelelaan
Amsterdam and Martini Hospital, Groningen
HV 1081 Amsterdam
The Netherlands
e-mail: G.Giaccone@vumc.nl

D. Granberg
Department of Endocrine Oncology
University Hospital
S-751 85 Uppsala
Sweden
e-mail: Dan.Granberg@medsci.uu.se

S. Goodin
UMDNJ/Robert Wood Johnson Medical School
Department of Medicine
The Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08901-1914
USA

W.N. Hait
UMDNJ/Robert Wood Johnson Medical School
Departments of Medicine & Pharmacology
The Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08901-1914
USA
e-mail: haitwn@umdnj.edu
Alt. e-mail: semlerka@umdnj.edu

D. Hamilton
Department of Pharmacology and Therapeutics
The Montreal Center for Experimental
Therapeutics in Cancer
D-127, Sir Mortimer B. Davis - Jewish
General Hospital
3755 Chemin Côte Ste Catherine
Montréal, Québec
Canada, H3T-1E2

K.R. Hande
777 Preston Research Building
Vanderbilt/Ingram Cancer Center
Vanderbilt University
Nashville, TN 37232
USA
e-mail: Kenneth.Hande@Vanderbilt.Edu

J.A. Hank
University of Wisconsin Comprehensive
Cancer Center
600 Highland Avenue, K4/414
Madison, WI 53792
USA

C. Harper-Wynne
Department of Medicine, Breast Unit
Royal Marsden Hospital
Fulham Road
London, SW3 6JJ
UK

R.S. Herbst
Department of Cancer Biology, Radiation
University of Texas MD Anderson Cancer Center
Houston, TX, 70030-4009
USA
e-mail: rherbst@mdanderson.org

D. Hershock
Assistant Professor of Medicine
Department of Hematology/Oncology
Abramson Cancer Center
16 Penn Tower
Hospital of the University of Pennsylvania
34th and Spruce Streets
Philadelphia, PA 19104
USA
e-mail: diane.hershock@uphs.upenn.edu

H.S. Hochster
160 East 32nd Street
New York, NY 10016
USA
e-mail: howard.hochster@med.nyu.edu

H.I. Hurwitz
Duke University Medical Center
Durham, NC
USA

T. Isobe
Department of Cancer Biology, Radiation
University of Texas MD Anderson Cancer Center
Houston, TX, 70030-4009
USA

M.C. Jensen
Cancer Immunotherapeutic Program
City of Hope NCI-Designated
Comprehensive Cancer Center
City of Hope Beckman Research
Institute & National Medical Center
Duarte, CA
USA
e-mail: mjensen@coh.org

I. Judson
Department of Cancer Therapeutics
Block E, Institute of Cancer Research
Cancer Research UK

15 Cotswold Road
Belmont, Sutton Surrey SM2 5NG
UK

M. Kalos
Cancer Immunotherapeutic Program
City of Hope NCI-Designated
Comprehensive Cancer Center
City of Hope Beckman Research
Institute & National Medical Center
Duarte, CA
USA

J.C. Karl
Bldg. 10, Rm 13N240,
10 Center Drive
MSC 1928
Bethesda, MD 20892
USA

T. Kieber-Emmons
Arkansas Cancer Research Center
University of Arkansas for Medical Sciences
Little Rock, AR 72205

J.M. Kirkwood
The University of Pittsburgh Cancer Institute
Melanoma Center
5117 Center Avenue
Pittsburgh, PA 15213-2584
USA
e-mail: KirkwoodJM@upmc.edu

Y.-J. Ko
Beth Israel Deaconess Medical Center
Harvard Medical School
Kirstein 158
330 Brookline Avenue
Boston, MA 02215
USA
e-mail: yoo-joung.ko@sw.ca

P.A. Konstantinopoulos
The University of Pittsburgh Cancer Institute
Melanoma Center
5117 Center Avenue
Pittsburgh, PA 15213-2584
USA

M. Kreditor
160 East 32nd Street
New York, NY 10016
USA

P. LoRusso
Karmanos Cancer Institute
Detroit, MI
USA

L.G. Lum
Immunotherapy Program
Adele R. Deof Cancer Center
North Campus Room G01
Roger Williams Hospital
825 Chalkstone Avenue
Providence, RI 02908
USA
e-mail: llum@rwmc.org

and

Department of Medicine
Division of Hematology/Oncology
Boston University School of Medicine

W. Luo
Department of Immunology
Roswell Park Cancer Institute
Elam & Carlton Streets
Buffalo, NY 14263
USA

C.L. Mackall
Bldg 10, Rm 13N240,
10 Center Drive
MSC 1928
Bethesda, MD 20892
USA
e-mail: cm35c@nih.gov

M. Magagnoli
Assistant, Department of Medical Oncology
and Hematology,
Istituto Clinico Humanitas
Via Manzoni 56
20089 Rozzano-Milano
Italy

M. Markman
Mail Box 121, M.D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
USA
e-mail: MMarkman@mdanderson.org

D. Martincic
777 Preston Research Building
Vanderbilt/Ingram Cancer Center
Vanderbilt University
Nashville, TN 37232
USA

D.G. McNeel
Department of Medicine
University of Wisconsin
K4/518 Clinical Science Center
600 Highland Avenue
Madison, WI 53792
USA
e-mail: dm3@medicine.wisc.edu

S.J. Moschos
The University of Pittsburgh Cancer
Institute Melanoma Center
5117 Center Avenue
Pittsburgh, PA 15213-2584
USA

Y. Nieto
University of Colorado Bone Marrow
Transplant Program
4200 East Ninth Avenue, B#190
Denver, CO 80262
USA
e-mail: yago.nieto@uchsc.edu

K. Öberg
Department of Endocrine Oncology
University Hospital
S-751 85 Uppsala
Sweden

F. Odicino
Department of Obstetrics & Gynaecology
Division of Gynaecology & Oncology
University of Brescia
Italy

B. Pasinetti

Department of Obstetrics & Gynaecology
Division of Gynaecology & Oncology
University of Brescia
Italy

S. Pecorelli

Department of Obstetrics & Gynaecology
Division of Gynaecology & Oncology
University of Brescia
Italy

M.A. Perales

Department of Medicine &
Swim Across America Laboratory
Memorial Sloan Kettering Cancer Center
New York, NY
USA

J.K. Puschel

Barrow Neurological Institute
500 West Thomas Street, Suite 300
Phoenix, AZ 85013
USA

A. Raubitschek

Cancer Immunotherapeutic Program
City of Hope NCI-Designated
Comprehensive Cancer Center
City of Hope Beckman Research Institute &
National Medical Center
Duarte, CA
USA

A. Ring

Department of Medicine, Breast Unit
Royal Marsden Hospital,
Fulham Road,
London, SW3 6JJ
UK

E. Rubin

UMDNJ/Robert Wood Johnson Medical School
Departments of Medicine & Pharmacology
195 Little Albany Street
New Brunswick, NJ 08901-1914
USA

A. Santoro

Director, Department of Medical Oncology
and Hematology
Istituto Clinico Humanitas
Via Manzoni 56, 20089 Rozzano-Milano
Italy
e-mail: Armando.santoro@humanitas.it

G.K. Schwartz

Department of Medicine
Division of Solid Tumor Oncology, and
Laboratory of New Drug Development
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10021
USA

M. Scurr

Department of Cancer Therapeutics
Block E, Institute of Cancer Research
Cancer Research UK
15 Cotswold Road
Belmont, Sutton Surrey SM2 5NG
UK
e-mail: mscurr@icr.ac.uk

M.A. Shah

Department of Medicine
Division of Solid Tumor Oncology, and
Laboratory of New Drug Development
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10021
USA
e-mail: shahl@mskcc.org

W.R. Shapiro

Barrow Neurological Institute
500 West Thomas Street, Suite 300
Phoenix, AZ 85013
USA

E. Smit

Division of Medical Oncology
Vrije Universiteit Medical Center
1117 De Boelelaan
Amsterdam and Martini Hospital, Gronigen
HV 1081 Amsterdam
The Netherlands

I. Smith
Department of Medicine, Breast Unit
Royal Marsden Hospital
Fulham Road
London, SW3 6JJ
UK
e-mail: ian.smith@rmh.nthames.nhs.uk

P.M. Sondel
University of Wisconsin Comprehensive
Cancer Center
600 Highland Avenue, K4/414
Madison, WI 53792
USA

W. Sun
16 Penn Tower
3400 Spruce Street
University of Pennsylvania Cancer Center
Philadelphia, PA 19104-4283
USA
e-mail: weijing.sun@uphs.upenn.edu

J. Stebbing
Department of Oncology
Chelsea & Westminster Hospital
369 Fulham Road
London, SW10 9NH
UK

C.H. Takimoto
Associate Professor
University of Texas Health Science Center at
San Antonio Cancer Therapy & Research Center
7979 Wurzbach Road, Room Z415
San Antonio, TX 78229
USA
e-mail: ctakimot@idd.org

H. van den Berg
Department of Paediatric Oncology
Emma Children's Hospital
Academic Medical Centre
University of Amsterdam
Room F8-242, PO Box 22700
1100 DD Amsterdam
The Netherlands
e-mail: h.vandenberg@amc.uva.nl

X. Wang
Department of Immunology
Roswell Park Cancer Institute
Elam & Carlton Streets
Buffalo, NY 14263
USA

P.H. Wiernik
Director, Our Lady of Mercy Cancer Center
New York Medical College
600 East 233rd Street
Bronx, NY 10466
USA

and

Professor of Medicine and Radiation Oncology
New York Medical College
Valhalla, NY
USA
e-mail: Pwiernik@aol.com

S.S. Wilson
Department of Urologic Oncology
Anschutz Cancer
Pavillion Denve
1665 North Ursula Street, Suite 1004
Aurora, CO 80010
USA
e-mail: shandra.wilson@uchsc.edu

J.D. Wolchok
Clinical Immunology Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center and
Weill Medical College of Cornell University
1275 York Avenue
New York, NY 10021
USA
e-mail: wolchokj@mskcc.org

T. Zaks
16 Penn Tower
3400 Spruce Street
University of Pennsylvania Cancer Center
Philadelphia, PA 19104-4283
USA

Introduction

This 22nd volume of *Cancer Chemotherapy and Biologic Response Modifiers* continues in the tradition of providing a timely review of progress and achievements in clinical oncology. As for past annuals, our emphasis is on recent advances in our understanding of anti-cancer drugs, specific malignancies and biological response modifiers, rather than the provision of a comprehensive overview. In order to accomplish this, we are committed to providing useful and clear reviews of the most important perspectives in oncology that have been identified over the past year. Thus, each volume reflects a spectrum of chapters presenting new data, conclusions and recommendations beyond those included in previous annuals. Of the 37 chapters in this volume, 16 are timely updates from the authors of chapters in volume 21; 7 are chapters by new authors, providing a different perspective on topics presented last year; and 14 are entirely new chapters by new authors, reflecting the rapid progress in this field.

The section on drugs includes new chapters on clinical use of epidermal growth factor receptor pathway inhibitors and on angiogenesis pathway inhibitors. These agents have moved rapidly from preclinical models to demonstrated clinical efficacy, and, with the recent FDA approval of cetuximab and bevacizumab, are becoming part of comprehensive oncologic care. The section on tumors provides detailed updates on the past year's advances in our understanding of risk, classification, staging and management of common malignancies. The section on biologics is comprised of five new chapters. Two provide perspective on active immunotherapy through vaccines or cytokine administration. Two provide exciting perspectives on how T cells can be modified to recognize tumor using tumor-reactive monoclonal antibody, via surface labeling with bispecific antibody, or by transfecting the T cells to express antibody-based 'chimeric receptors'. Finally, the biologics section includes an important review detailing the effects of conventional cancer treatment on the patient's immune system, based on state-of-the-art immunologic assessment methodology.

As in the past two annuals, we are pleased to include a special section focused on a disease that has been the target of recent advances. This volume's special section is devoted to recent advances in our understanding and treatment of melanoma. Special detail is included regarding advances in screening, prevention and predisposition for this increasingly frequent disease. Surgical treatment remains the mainstay of therapy for patients diagnosed with localized low-risk melanoma; biologic response modifiers (immune-based therapy) are the prime interventions for patients with higher risk and advanced disease. Chapters on the uses of interferon, and on other cytokines combined with chemotherapy, designated 'biochemotherapy', summarize how and when these approaches have proven to be useful. Four chapters then review separate classes of immunologic interventions for melanoma: the use of vaccination with tumor antigens in the form of peptides or gangliosides; vaccination using DNA that encodes antigens that should induce anti-tumor immunity; novel vaccination strategies using anti-idiotypic monoclonal antibody, or peptide mimics of tumor antigens, to activate T and B cell immunity; and finally the use of melanoma reactive monoclonal antibodies and fusion proteins derived from them.

We thank the authors of these chapters for their state-of-the-art reviews and Elsevier for providing leadership, administrative support, and vision for the production of this 22nd volume in this series. Finally, we thank the researchers and clinicians who have appreciated that the unique information that can be included in this form of a timely annual provides an important and useful complement to traditional textbooks and periodicals.

THE EDITORS

Contents

Introduction	xvii
I DRUGS	
1. Thymidylate synthase inhibitors <i>C.H. Takimoto and S. Diggikar</i>	1
2. Anthracyclines <i>D. Hamilton and G. Batist</i>	19
3. Tubulin-targeting agents <i>W.N. Hait, E. Rubin and S. Goodin</i>	35
4. Recent developments in the clinical activity of topoisomerase-I inhibitors <i>M. Kreditor, M. Fink and H.S. Hochster</i>	61
5. Topoisomerase II inhibitors <i>D. Martincic and K.R. Hande</i>	101
6. Farnesyltransferase inhibitors <i>A.A. Adjei</i>	123
7. Cyclin-dependent kinases as targets for cancer therapy <i>M.A. Shah and G.K. Schwartz</i>	135
8. DNA-binding agents <i>Y. Nieto</i>	163
9. Epidermal growth factor receptor pathway inhibitors <i>J. Baselga and J. Cortes</i>	205
10. Angiogenesis pathway inhibitors <i>R.S. Herbst, P. LoRusso, T. Isobe and H.I. Hurwitz</i>	225

II BIOLOGICAL RESPONSE MODIFIERS

11. Prostate cancer antigens and vaccines, preclinical developments
D.G. McNeel 247
12. Systemic therapy for renal cell carcinoma
Y.-J. Ko and M.B. Atkins 263
13. Retargeting T cells and immune effector cells with bispecific antibodies
L.G. Lum and P.A. Davol 273
14. T-cell genetic modification for re-directed tumor recognition
*L.J.N. Cooper, M. Kalos, D. DiGiusto, C. Brown,
S.J. Forman, A. Raubitschek and M.C. Jensen* 293
15. Cancer therapy-induced immune modulation
J.C. Karl and C.L. Mackall 325

III TUMOURS

16. Plasma cell dyscrasias and leukemias
P.H. Wiernik 343
17. Lymphomas
A. Santoro, L. Castagna and M. Magagnoli 391
18. Head and neck cancers
M. Al-Sarraf and S. Balaraman 401
19. Lung cancer
G. Giaccone and E. Smit 413
20. Cancers of the large bowel and hepatobiliary tract
T. Zaks and W. Sun 443
21. Neuroendocrine tumours
D. Granberg and K. Öberg 471
22. Genitourinary malignancies
S.S. Wilson and E.D. Crawford 485

23.	Systemic therapy for gynecological neoplasms: Ovary, cervix, and endometrium <i>S. Pecorelli, B. Pasinetti, R. Angioli, G. Favalli and F. Odicino</i>	515
24.	Breast cancer <i>A. Ring, C. Harper-Wynne and I. Smith</i>	545
25.	Melanoma <i>S.J. Moschos, P.A. Konstantinopoulos and J.M. Kirkwood</i>	563
26.	Soft-tissue and bone sarcomas <i>M. Scurr and I. Judson</i>	591
27.	Central nervous system tumors <i>L.S. Ashby, J.K. Pueschel and W.R. Shapiro</i>	605
28.	Biology and therapy of malignant solid tumors in childhood <i>H. van den Berg</i>	643
29.	Supportive care <i>M. Markman</i>	677
30.	AIDS-associated malignancies <i>M. Bower and J. Stebbing</i>	687
IV	MELANOMA AND BIOLOGICAL RESPONSE MODIFIERS IN THE TREATMENT OF MELANOMA	
31.	Genetics, prevention and screening for melanoma <i>D. Hershock</i>	707
32.	Current status of interferon- α in the treatment of melanoma <i>A.M.M. Eggermont</i>	729
33.	Chemotherapy, cytokines, and biochemotherapy for melanoma <i>O. Eton</i>	739
34.	Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses <i>M.A. Perales and P.B. Chapman</i>	749

35.	DNA vaccines for melanoma <i>A.D. Cohen and J.D. Wolchok</i>	761
36.	Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: Implications for immunotherapy of malignant diseases <i>W. Luo, J. Chi-feng Hsu, T. Kieber-Emmons, X. Wang and S. Ferrone</i>	769
37.	Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma <i>M.R. Albertini, J.A. Hank and P.M. Sondel</i>	789
	Abbreviations of drugs	799
	Abbreviations of chemotherapeutic combinations	803
	Biological abbreviations	807
	NSC-numbers	812
	Subject index	813